Member Info for Sundayroast

Seems like a decent update of what we already know.

SatoshiPay is growing exponentially and will create real value here.

I can see a major bounce from these levels.

Looks at the 3 year chart.

Sometimes MMs drop the SP dramatically when it nears major SR levels to triggers stop losses.

The company is in a much better position than they have ever been.

Some good news and this will spike again.

From this level you could see 4-5 bags.

No RNS today means it was panic selling, this is when its the best time to buy, rather on hype of a spike

Just bounced of major SR level.

Massively undervalued, expect a big bounce from these levels.

NAV per share as at the period end was 1.98 pence (31 December 2024)

Since then the company is in a much stronger position.

Vizgard selected for NATO technology alliance, is huge for Vizgard and MFAI.

I would be surprised that NAV is more than 3p a share now.

At some point soon investors will notice how undervalued this is and it will muti bag.

Buy and accumulate at these silly low levels

Ticking ip again, love shares like this. No noise just a steady re-rate.

I did slice a small bit today as I bought at 11p.

Had a share i really wanted to buy some more of.

But holding the rest for bigger gains here

Bought some more this morning.

Love shares like this. Massive asset base, trading well below NAV. Tiny MC. Makes them prime target for big spikes. Accumulate whilst quiet and wait.

I did the same with ORCP and made a fortune

Trading so much below NAV. I can see this rocketing at some point. I'm in and waiting, very little downside

Will be trading over 20p soon.

Still massively undervalued.

I think we could easily see 30p on news

Fantastic news, everything is coming nicely together here.

Looking like it could be on the next leg up!

The fundamentals here haven't changed. Just standard SP action.

Project 3 Farm In could be any day and we could see 100% rise easy.

Thats why i haven't sold a bean, I wouldn't want to be caught with my pants down.

I will be buying more if it drops further

Considering it went from 7p to almost 30p on the spike last year your talking absolute rubbish.

CRTX is in a far superior position now starting ph2 human trails with FDA OOD approval any day now.

Fully funded fornthe rest of the year.

I expect there is a lot of interest from big pharna in CRTX.

30p + could easily be on the cards here.

We are so undervalued from what stage in development we're at.

Poor de-ramping D-

Buyers will pile into this soon, great news for the company.

I've just bought the dip

Feels like this is about to blow!

The significance of this being registration grade phase 2 trials is massive.

Means that phase 3 trails may not be required.

I expect a lot of big pharma have eyes on CRTX.

Fully funded for phase 2.

Grants and partnerships will come.

MM's walking this up on small volume.

Re-rate behaviour, reached 29p may last year.

When good news lands it could smash through that!

On the move again, This will be 20p in no time.

Agreed, I think once they announce ph2 trails or FDA OOD confirmation then this will rocket. Its so undervalued compared to its piers.

CRISM (CRTX) – £6m mcap

Current status

• Two programmes:

1. Glioblastoma (GBM) – Phase 2 starting Q1 2026

2. Prostate cancer – strong preclinical data, validated delivery concept

Key points:

• They already have MHRA + Ethics approval for the Phase 2 GBM trial.

• The trial design is registration-grade Phase 2, meaning:

• If efficacy is strong + safety acceptable → may jump straight to Phase 3 or even conditional approval conversations.

Platform value

Their ChemoSeed delivery tech is:

• Localised

• Sustained release

• Uses generic chemotherapy

• Avoids systemic toxicity

• Potentially high-value in multiple cancers

This is exactly the type of platform big pharma likes to license because:

• Cheap to develop

• Uses known drugs (low regulatory risk)

• High unmet need (GBM, prostate, pancreatic, etc.)

Valuation read

£6m mcap is absurdly low for:

• A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential)

• A second programme with strong preclinical validation

• A platform that can generate multiple assets

This is seed-stage pricing with mid-stage capability